Melatonin Treatment for Tardive Dyskinesia in Schizophrenia

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120 patients with established tardive dyskinesia (TD). This study addresses a free radical hypothesis of TD.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing HuiLongGuan Hospital
• Collaborator: Stanley Medical Research Institute
• Treatments: Antioxidants; Melatonin

Criteria

Inclusion Criteria:

1. diagnosis of both schizophrenia and TD;

2. duration of TD symptoms longer than 1 year;

3. on stable doses of antipsychotic drug for at least 6 months;

4. between 18 and 70 years of age.

Exclusion Criteria:

1. comorbid neurological illness other than TD;

2. if they have received vitamin C or vitamin E within 1 month before the start of the study;

3. alcohol/drug abuse;

4. acute, unstable medical condition;

5. pregnant or breastfeeding female;

6. use of other antioxidants.